20431T

9/10

その他参考文献 1） Smith TJ, Bohlke K, Lyman GH, et al, American Society of Clinical Oncology. Recommendations for the Use of WBC Growth Factors：American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015；33：3199‒212. 2） Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia：ESMO Clinical Practice Guide-lines. Ann Oncol. 2016；27（suppl 5）：v111‒8. 3） NCCN Clinical Practice Guidelines in Oncology. Hematopoietic Growth Factors Version 1. 2022 4） Yamao K, Takenaka M, Yoshikawa T, et al. Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G‒CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX：A Single‒center Retrospective Study. Intern Med. 2019；58：1993‒2002. 5） Leonard RC, Mansi JL, Keerie C, et al. A randomised trial of secondary prophylaxis using granulocyte colony‒stimulating factor（‘SPROG’trial）for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo‒Celtic Cooperative Group and NCRN. Ann Oncol. 2015；26：2437‒41. 6） Freyer G, Jovenin N, Yazbek G, et al. Granocyte‒colony stimulating factor（G‒CSF）has significant efficacy as secondary prophylaxis of chemotherapy‒induced neutropenia in patients with solid tumors：results of a pro-spective study. Anticancer Res. 2013；33：301‒7. 7） Meisel A, von Felten S, Vogt DR, et al. Severe neutropenia during cabazitaxel treatment is associated with sur-vival benefit in men with metastatic castration‒resistant prostate cancer（mCRPC）：A post‒hoc analysis of the TROPIC phase Ⅲ trial. Eur J Cancer. 2016；56：93‒100. 8） Sakurada T, Bando S, Zamami Y, et al. Prophylactic administration of granulocyte colony‒stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients：a retrospective study. Cancer Chemother Pharmacol. 2019；84：1107‒14. 9） Vitolo U, Angrili F, DeCosta L, et al. G‒CSF use in patients receiving first‒line chemotherapy for non‒Hodgkin’s lymphoma（NHL）and granulocyte‒colony stimulating factors（G‒CSF）as observed in clinical practice in Italy. Med Oncol. 2016；33：139. 10） Julius JM, Hammerstrom A, Wei C, et al. Defining the impact of the use of granulocyte colony stimulating factors on the incidence of chemotherapy‒induced neutropenia in patients with gynecologic malignancies. J Oncol Pharm Pract. 2017；23：121‒7. 11） Tesch H, Ulshöfer T, Vehling‒Kaiser U, et al. Prevention and treatment of chemotherapy‒induced neutropenia with the biosimilar filgrastim：a non‒interventional observational study of clinical practice patterns. Oncol Res Treat. 2015；38：146‒52. 12） Rueda A, Sevilla I, Gumà J, et al. Secondary prophylactic G‒CSF（filgrastim）administration in chemotherapy of stage Ⅰ and Ⅱ Hodgkin’s lymphoma with ABVD. Leuk Lymphoma. 2001；41：353‒8. 13） Gupta S, Singh PK, Bhatt ML, et al. Efficacy of granulocyte colony stimulating factor as a secondary prophylaxis along with full‒dose chemotherapy following a prior cycle of febrile neutropenia. Biosci Trends. 2010；4：273‒8. 14） Graczyk J, Cheung MC, Buckstein R, et al. Granulocyte colony‒stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced‒stage Hodgkin lymphoma treated with adriamycin, bleomy-cin, vinblastine and dacarbazine chemotherapy：a decision analysis. Leuk Lymphoma. 2014；55：56‒62.Q40（CQ）　157あった。委員からの事前申告に基づき，経済的COI・アカデミックCOIによる推奨決定への影響はないと判断された。　システマティックレビューレポートに基づいて，推奨草案「がん薬物療法を受けて発熱性好中球減少症を発症した固形がん患者において，G‒CSFの二次予防投与を行うことを弱く推奨する」が，「特に治癒を含む十分な効果を期待でき，治療強度を下げない方がよいと考えられる疾患」という注釈とともに提示された。推奨決定の協議と投票の結果，23名中23名が原案に賛同し合意形成に至った。Ⅵ